Free Trial

FY2024 Earnings Estimate for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals logo with Medical background

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Recursion Pharmaceuticals in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.48) for the year, down from their prior estimate of ($1.45). The consensus estimate for Recursion Pharmaceuticals' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals' Q4 2024 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business's quarterly revenue was up 147.6% compared to the same quarter last year. During the same period last year, the business earned ($0.43) earnings per share.

Several other analysts have also recently weighed in on RXRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $8.75.

Read Our Latest Stock Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded down $0.20 during mid-day trading on Friday, reaching $7.33. The company had a trading volume of 25,117,360 shares, compared to its average volume of 17,134,949. The business has a fifty day simple moving average of $6.88 and a 200 day simple moving average of $6.95. The company has a market cap of $2.86 billion, a P/E ratio of -4.79 and a beta of 0.85. Recursion Pharmaceuticals has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares of the company's stock, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,894 shares of company stock valued at $279,279. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RXRX. Axxcess Wealth Management LLC raised its position in shares of Recursion Pharmaceuticals by 4.3% during the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company's stock worth $289,000 after purchasing an additional 1,795 shares during the period. Green Alpha Advisors LLC increased its stake in Recursion Pharmaceuticals by 2.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock valued at $427,000 after purchasing an additional 1,800 shares in the last quarter. Wedmont Private Capital raised its holdings in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock worth $144,000 after buying an additional 2,000 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company's stock worth $346,000 after acquiring an additional 2,667 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?

Before you consider Recursion Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.

While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines